On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Human NAT1: overview
- NAT1 specific ligands
- Screening for NAT substrates & inhibitors
- Biomarker detection in breast cancer (1)
- Biomarker detection in breast cancer (2)
- A single binding site
- Naphthoquinone inhibits acetylation activity
- Naphthoquinone 1 inhibits AcCoA hydrolysis
- R127 mutation blocks inhibition by naphthoquinone
- R127 in hNAT1 and mNAT2
- Improving NAT1 detection
- NAT1 knock-down alters cell growth & survival
- Status of NAT1 research
- Arylamine N-acetyltransferases (recap)
- Nat in fungi metabolise anti-fungal toxin
- Activity of fungal Nat enzymes
- Nat in prokaryotes including mycobacteria
- Prokaryotic Nats
- Active site of Mycobacterium smegmatis Nat
- Active site of Pseudomonas aerogunosa Nt
- Life cycle of M. tuberculosis
- Return to N-acetylation of isoniazid (INH)
- KatG and Nat
- Nats in prokaryotes
- Nats affect lipid levels in cells
- M. bovis BCG phenotype in nat KO cells (1)
- M. bovis BCG phenotype in nat KO cells (2)
- M. bovis BCG phenotype in nat KO cells (3)
- M. bovis BCG phenotype in nat KO cells (4)
- Inhibiting Nat and mycolic acid
- Summary: alteration of nat expression
- Mycobacterial Nat specific ligands
- Detecting Nat substrates & inhibitors
- Mycobacterial Nat inhibitors identified from screen
- Nat as an anti-tubercular target
- Triazole vs. mycobacteria
- Growth inside macrophage is affected
- Synthetic analogues of 190
- Docking the compound into the active site of Nat
- Piperidinol inhibition of mycobacterial Nat
- Inhibition by piperidinol
- Piperidinol in the presence of mycobacterial Nat
- Binding of piperidinol fragment
- Structure of TB Nat now available
- TB Nat inhibitors
- Summary: chemical inhibition
- The future
- Acknowledgments
Topics Covered
- Mechanism of action
- Reaction substrates
- Isoform substrate profiles
- Isoenzymes NAT1 and NAT2
- Regulation of gene expression
- Pharmacogenetics
- Phenotype/genotype correlation
- Ethnic variation
- Transgenic mouse models
- NAT protein structures
- NAT as a biomarker in breast cancer
- NAT inhibitors as diagnostic agents
- NAT in mycobacteria
- NAT inhibitors as an approach to potential anti-tubercular agents
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sim, E. (2016, July 28). Arylamine N-acetyltransferases 3 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/IDJJ9816.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Edith Sim has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Arylamine N-acetyltransferases 3
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Arylamine
N-acetyltransferases. Part 3
I'm Edith Sim,
and I have been working
on these enzymes
for over 20 years.
0:10
So human NAT1, to recap,
is widespread in
tissue distribution,
shows genetic polymorphism,
N-acetylates p-aminobenzoic acid,
and N-acetylates p-abaglu
a folate catabolite.
It hydrolyses acetylCoA
in the presence of folate.
It's clearly expressed in
early development.
It's over-expressed
in ER positive breast cancer.
And it's linked to folate
and acetylCoA homeostasis.
0:40
In order
to explore this further,
it was felt important
to identify
NAT1 specific inhibitors.
0:51
This was done, again,
you've seen this slide before,
but just to emphasize,
this was done to allow a library
of over 5,000 compounds
to be screened
with recombinant
specific enzymes
including human NAT1.
1:11
What came out of this
was a specific NAT1 inhibitor,
identified as naphthoquinone,
which when it binds
to human NAT1
changes color from red to blue.
This is important
because if NAT1 is a biomarker
for breast cancer,
then having something
which would
specifically detect it
is particularly important.